Thermoablation: a new tool in the fight against cervical cancer

Abstract

The World Health Organization's (WHO) global strategy to eliminate cervical cancer is based on prevention, screening, and timely treatment, promoting the "Screen-and-Treat" model. Cervical thermoablation emerges as an ideal tool for implementing this model, as it is effective, safe, and easily accessible in outpatient settings. Objective: To evaluate the efficacy, safety, and clinical acceptance of the cervical thermoablation procedure using the Thermoglide device in the treatment of low-grade squamous intraepithelial lesions (CIN I) of the cervix in patients seen at the gynecologic oncology clinic of the La Trinidad Teaching Medical Center. Materials and Methods: A prospective, longitudinal, observational clinical study was designed. The sample will be non-probabilistic convenience sampling, estimated at 32 patients with a confirmed diagnosis of CIN I who meet the selection criteria. The thermoablation procedure was performed, and a six-month follow-up was conducted to evaluate cytological regression and the incidence of adverse effects. Results: The sample of 32 patients had a mean age of 33.1 years. The majority of the population was nulliparous (53.1%). Thermoablation with the Thermoglide device showed a 100.0% regression rate at six months, confirming complete efficacy for the treatment of CIN I lesions in the studied sample. The mean pain score of 3.0 is classified as mild, with 71.9% of patients reporting exactly a VAS 3. Overall acceptance was unanimous (100.0%).